<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005505'>Refractory anemia</z:hpo> (RA) in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are very <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> diseases regarding their <z:mp ids='MP_0000002'>morphology</z:mp>, clinical features and survival </plain></SENT>
<SENT sid="1" pm="."><plain>We proposed the new designations 'RA with severe <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (RASD)' and 'RA with minimal <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (RAminiD)' </plain></SENT>
<SENT sid="2" pm="."><plain>In our criteria, RASD is considered present if a bone marrow (BM) examination shows Pseudo-<z:e sem="disease" ids="C0865271" disease_type="Disease or Syndrome" abbrv="">Pelger-Huet anomalies</z:e> of mature neutrophils &gt; or =3% and/or micromegakaryocytes (mMgk) of megakaryocytes &gt; or =10% in RA patients </plain></SENT>
<SENT sid="3" pm="."><plain>RAminiD is defined as RA cases other than RASD </plain></SENT>
<SENT sid="4" pm="."><plain>After the reclassification of 58 primary RA patients, the group was composed of 45 RAminiD and 13 RASD patients </plain></SENT>
<SENT sid="5" pm="."><plain>The blast percentage in the BM and the frequency of cytogenetic abnormalities observed in the RASD patients were intermediate between those in the RAminiD and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> patients </plain></SENT>
<SENT sid="6" pm="."><plain>The analysis of survival curves revealed differences among the three groups; the RASD patients had lower survival probabilities than those of the RAminiD group, and significantly higher probabilities than those of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> group </plain></SENT>
<SENT sid="7" pm="."><plain>(RAminiD vs RASD, P=0.06; RASD vs <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, P=0.004.) Our data indicate that in RA patients, RASD is a distinct subset of RA with an unfavorable clinical outcome </plain></SENT>
</text></document>